Table 1. Baseline Characteristics of the ALLHAT-LLT Participants by Treatment Group (Pravastatin vs Usual Care) and Age Group.
| Characteristic | 65-74 y | ≥75 y | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pravastatin Sodium | Usual Care | P Value | Pravastatin | Usual Care | P Value | Pravastatin | Usual Care | P Value | |
| No. | 1092 | 1049 | NA | 375 | 351 | NA | 1467 | 1400 | NA |
| Age, mean (SD), y | 68.8 (2.7) | 68.8 (2.8) | .61 | 78.5 (3.6) | 78.6 (3.6) | .86 | 71.3 (5.2) | 71.2 (5.2) | .68 |
| Female, No. (%) | 490 (44.9) | 513 (48.9) | .06 | 214 (57.1) | 198 (56.4) | .86 | 704 (48.0) | 711 (50.8) | .13 |
| Race/ethnicity, No. (%) | |||||||||
| White non-Hispanic | 436 (39.9) | 419 (39.9) | .21 | 145 (38.7) | 136 (38.7) | .87 | 581 (39.6) | 555 (39.6) | .63 |
| Black non-Hispanic | 387 (35.4) | 363 (34.6) | 121 (32.3) | 115 (32.8) | 508 (34.6) | 478 (34.1) | |||
| White Hispanic | 167 (15.3) | 190 (18.1) | 78 (20.8) | 67 (19.1) | 245 (16.7) | 257 (18.4) | |||
| Black Hispanic | 47 (4.3) | 31 (3.0) | 11 (2.9) | 14 (4.0) | 58 (4.0) | 45 (3.2) | |||
| Other | 55 (5.0) | 46 (4.4) | 20 (5.3) | 19 (5.4) | 75 (5.1) | 65 (4.6) | |||
| Years of education, mean (SD) | 10.5 (4.4) | 10.6 (4.1) | .72 | 9.3 (4.3) | 9.2 (4.5) | .79 | 10.2 (4.4) | 10.3 (4.3) | .86 |
| Medication use, No./total No. (%) | |||||||||
| Women taking estrogen | 59/490 (12.0) | 60/513 (11.7) | .87 | 15/214 (7.0) | 11/198 (5.6) | .54 | 74/704 (10.5) | 71/711 (10.0) | .75 |
| Aspirin | 276/1092 (25.3) | 254/1049 (24.2) | .57 | 98/375 (26.1) | 100/351 (28.5) | .48 | 374/1467 (25.5) | 354/1400 (25.3) | .90 |
| Antihypertensive medication | 994/1092 (91.0) | 948/1049 (90.4) | .60 | 325/375 (86.7) | 326/351 (92.9) | .01 | 1319/1467 (89.9) | 1274/1400 (91.0) | .32 |
| Current cigarette smoking, No. (%) | 290 (26.6) | 247 (23.5) | .11 | 51 (13.6) | 53 (15.1) | .56 | 341 (23.2) | 300 (21.4) | .24 |
| Type 2 diabetes, No. (%) | 552 (50.5) | 544 (51.9) | .55 | 196 (52.3) | 171 (48.7) | .34 | 748 (51.0) | 715 (51.1) | .97 |
| BMI, mean (SD) | 29.9 (5.9) | 30.0 (5.9) | .79 | 28.4 (5.4) | 28.2 (5.1) | .55 | 29.5 (5.8) | 29.5 (5.8) | .99 |
| >30, No. (%) | 476 (43.6) | 441 (42.0) | .45 | 123 (32.8) | 109 (31.1) | .62 | 599 (40.8) | 550 (39.3) | .38 |
| Blood pressure, mean (SD), mm Hg | |||||||||
| Systolic | 146.9 (15.3) | 146.9 (15.3) | .95 | 150.6 (15.0) | 147.5 (16.1) | .01 | 147.8 (15.3) | 147.1 (15.5) | .19 |
| Diastolic | 84.0 (9.5) | 83.9 (10.1) | .92 | 82.1 (11.2) | 82.0 (9.7) | .88 | 83.5 (10.0) | 83.4 (10.0) | .88 |
| Fasting glucose, mean (SD), mg/dL | 132.1 (60.2) | 128.5 (57.2) | .21 | 127.4 (61.6) | 127.9 (61.8) | .92 | 130.9 (60.5) | 128.4 (58.4) | .30 |
| Lipid values | |||||||||
| Serum cholesterol, mean (SD), mg/dL | 225.5 (25.5) | 225.8 (24.6) | .81 | 225.1 (23.8) | 225.7 (26.2) | .74 | 225.4 (25.1) | 225.8 (25.0) | .70 |
| LDL-C, mean (SD), mg/dL | 148.0 (20.4) | 147.9 (19.3) | .90 | 146.6 (18.1) | 146.8 (19.7) | .93 | 147.7 (19.8) | 147.6 (19.4) | .95 |
| LDL-C <130 mg/dL, No. (%) | 243 (22.3) | 201 (19.2) | .09 | 64 (17.1) | 73 (20.8) | .21 | 307 (20.9) | 274 (19.6) | .40 |
| HDL-C, mean (SD), mg/dL | 46.7 (12.8) | 47.1 (13.8) | .47 | 48.8 (13.9) | 50.2 (14.3) | .17 | 47.2 (13.1) | 47.9 (14.0) | .19 |
| Fasting triglycerides, mean (SD), mg/dL | 152.0 (66.5) | 151.3 (70.2) | .82 | 145.0 (62.4) | 142.3 (66.5) | .60 | 150.3 (65.6) | 149.0 (69.3) | .63 |
| Antihypertensive randomization, No. (%)a | |||||||||
| Chlorthalidone | 376 (34.4) | 379 (36.1) | .72 | 150 (40.0) | 128 (36.5) | .69 | 526 (35.9) | 507 (36.2) | .98 |
| Amlodipine | 242 (22.2) | 239 (22.8) | 90 (24.0) | 82 (23.4) | 332 (22.6) | 321 (22.9) | |||
| Lisinopril | 241 (22.1) | 214 (20.4) | 65 (17.3) | 69 (19.7) | 306 (20.9) | 283 (20.2) | |||
| Doxazosin | 233 (21.3) | 217 (20.7) | 70 (18.7) | 72 (20.5) | 303 (20.7) | 289 (20.6) | |||
| Years of follow-up, mean (SD) [maximum] | 4.63 (1.59) [7.78] | 4.77 (1.57) [7.83] | .04 | 4.32 (1.62) [7.39] | 4.32 (1.58) [7.20] | .99 | 4.55 (1.60) [7.78] | 4.66 (1.58) [7.83] | .08 |
Abbreviations: ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial–Lipid-Lowering Trial; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NA, not applicable.
SI conversion factors: To convert cholesterol levels to millimoles per liter, multiply by 0.0259; glucose level to millimoles per liter, multiply by 0.0555; and triglycerides level to millimoles per liter, multiply by 0.0113.
a
The ALLHAT randomization for chlorthalidone, amlodipine, lisinopril, and doxazosin mesylate was conducted in a ratio of 1.7:1:1:1.